The ESMO World Congress on Gastrointestinal Cancer represents the year’s most important gathering designed to focus on reversing the current global statistics that rank gastrointestinal malignancies as the leading causes of cancer deaths worldwide.
"The best congress in malignant GI management."

"Must-attend conference for any surgeon involved in GI cancer treatment."

"This is a must-attend congress!"

"It is a very important occasion to analyze news about gastrointestinal cancers."

"This is the first forum where new trial results are presented."

"I have always attended since the early 2000s and will definitely be attending again!"

"It was the first time I attended this meeting and I am very satisfied with the program, the organization, the timing, and the content. I will try to be a regular attendee as I strongly believe it will be very useful for expanding my knowledge in GI and liver cancer as well as improving my skills in providing the best new treatment implementations for my patients."
Attendee Demographics

Regions of the World Represented

- **54%** Western Europe
- **12%** Eastern Europe
- **11%** Middle East
- **8%** Asia
- **7%** North America
- **7%** South America
- **1%** Other

Attendee Specialties

<table>
<thead>
<tr>
<th>Medical Oncology</th>
<th>50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastroenterology</td>
<td>18%</td>
</tr>
<tr>
<td>Clinical Research</td>
<td>16%</td>
</tr>
<tr>
<td>Surgery/Surgical Oncology</td>
<td>9%</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>4%</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>3%</td>
</tr>
<tr>
<td>Nursing</td>
<td>1%</td>
</tr>
</tbody>
</table>

Attendee Survey Results

- **98%** of respondents learned something new as a result of this program
- **99%** of attendees say this program met their educational needs and increased their knowledge
- **99%** of attendees say they would recommend this Congress to a colleague
- **97.3%** of attendees say this program will improve the lives of their patients
Scientific Program Highlights

450+ Abstracts Published (Including 6 Late-Breaking)
120+ Scientific Sessions Covered
80+ GI Oncology Experts Presented

MOST NOTEWORTHY LATE-BREAKING ABSTRACT

BEACON CRC: A Randomized, Three-Arm, Phase-3 Study of Encorafenib and Cetuximab With or Without Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer
Presented by Scott Kopetz

KEYNOTE PRESENTATIONS

Managing Side Effects of IO Agents
Jeffrey Weber, New York

Novel Oral Anticoagulants and GI Cancer Patients
Mario Dicato, Luxembourg

MOST NOTEWORTHY SESSION

Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer
This session was introduced this year to focus on important phase I and II clinical trials in the field of GI cancer, which may have implications on treatment strategies in patients with gastrointestinal malignancies. The initial data presented on a wide variety of GI cancers are a gateway to the new drugs and approaches that will take center stage in the near future.

NEW GROUNDBREAKING RESEARCH

Emerging New or Combination Drugs in GI Cancer
In 2019, we hit a record-breaking number of abstracts submitted & accepted to the Congress. The list of some of the most impactful can be found below.

Abstracts Presented

» Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer; Shigenori Kadowaki, et al

» Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVD); Ian Chau, et al

» Debo 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: Preliminary results; Ignacio Matos, et al

» A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction; Marina Maglakelidze, et al

» A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus S-fluorouracil/leucovorin (S-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC); Zev Wainberg, et al

» Hafnium oxide nanoparticles activated by SBRT: A new interventional radiation therapy approach for the treatment of unresectable liver cancers; Thierry De Baere, et al

» Regorafenib plus nivolumab in patients with advanced colorectal (CRC) or gastric cancer (GC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603); Hiroki Hara, et al

» Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: Safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study; Philippe Cassigneau, et al

» Phase I studies assessing the safety and clinical activity of autologous and allogeneic NK92-D-based CAR-T therapy in metastatic colorectal cancer; Eric Van Cutsem, et al

» Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of the anti-EGFR Temuzotuximab (TO) in combination with the anti-MUC1 Gatipotuzumab (GAT) in patients with EGFR positive solid tumors; Elena Garralda, et al

Key Topics

Cancer of the Pancreas and Biliary Tract
Studying Value and Validity in Oncology
Esophageal and Gastric Cancers
Patient Factors in Disease Biology: Gender and Age
Young Medical Oncologists
Hepatocellular Cancer
Molecular Biology in Colorectal Cancer
Multimodality Therapy for Rectal Cancer
Immune Mechanisms and Immune Therapy
Colorectal Cancer
New Breakthroughs in Rare Cancers
Synchronous Oligometastatic Colorectal Cancer

WORLDGICANCER.COM
On-Site Social Media Engagement

#WorldGI2019

Twitter

41,800+
Impressions on Congress content
150 new followers since the Congress

Facebook

20,687
Followers

Impactful Tweets

Aparna Raj Parikh @aparnar124 · Jul 6
Great to see our upcoming @SU2C #quidiopsy guided trial highlighted in the adjuvant #colorectalcancer session #WorldGI2019 very excited for this trial to start later this year!

Mike Pishvaian @MPishvaian · Jul 4
I’m so excited to see the NRG1 data of @SushmaJonna and @StephenLiu being presented at #WorldGI2019, with an emphasis on #PancreaticCancer (also presented by @benwenbergmd earlier today). @LombardiCancer being represented across disciplines.

Sharlene Gill @GIISharlene · Jul 6
Emerging role of ctDNA assessment for minimal residual disease in the adjuvant colon setting - many studies ongoing including COBRA aka CCTG C0.29 in Canada. Look forward to this study opening soon! @WCGIC #WorldGI2019 @CDNCancerTrials @howiet2013 #crocsm @BCCancer

Rodrigo Dienstmann_MD @rdienstmann · Jul 6
“Beacon CRC” study shows impressive preliminary data: OS gain with triplet BRAF+EGFR+MEK vs. Irinotecan in BRAF V600E mut metastatic CRC. Long time we have not seen such KM in CRCI #WorldGI2018 Great job @skopetz @TaberneroJosep
Traffic on oncnet.com increased by 170% from June to July, with 121,480 pageviews for the ESMO World Congress on GI Cancer news coverage.

Top 5 Articles Published:

» Triplet Combo Regimen Defines New Standard of Care for Patients With BRAF V600E-Mutant Metastatic CRC

» New Classifications and Therapeutic Options for Pancreatic and Gastrointestinal NETs

» Efficacy of Trifluridine/Tipiracil Improved With Bevacizumab in Chemo-Refractory mCRC

» TAS-118 Plus Oxaliplatin Potential New Standard Therapy for Advanced Gastric Cancer

» Should Radiotherapy Be Included as Part of Adjuvant Therapy in Gastric Cancer?
Exhibits & Commercial Support

2019 Exhibitors

- AMGEN®
- Daiichi-Sankyo
- halio dx
- PANCREATIC CANCER EUROPE
- AMMF
- DIGESTIVE CANCERS EUROPE
- Halozyme
- Pierre Fabre
- Bayer
- erytech
- IPSEN
- SERVIER
- Biocartis
- Lilly
- SIRTeX
- CirLel
- ESMO
- Merck
- Wisepress.com
- CLDF
- ESDO
- Oxford Cancer Biomarkers
- Zero Gravity

New 2019 Congress Exhibitors

- 18 Digital Webcast Projects
- 15 Successful Symposia
- 1 ESMO Colloquium Program
- 2 Clinical Research Updates (CRU)
- 2 ESMO GI Clinical Forum